Pictet Asset Management (UK)’s Denali Therapeutics DNLI Stock Holding History

Pictet Asset Management (UK)’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$38.5M	Buy	491,372 +2,873	+0.6%	+$178K	0.04%	396
2021 Q1	$27.9M	Sell	488,499 -150,961	-24%	-$10.1M	0.03%	438
2020 Q4	$53.6M	Sell	639,460 -677,063	-51%	-$40.9M	0.07%	299
2020 Q3	$47.2M	Buy	1,316,523 +343,456	+35%	+$10.3M	0.07%	278
2020 Q2	$23.5M	Buy	973,067 +195,867	+25%	+$4.61M	0.04%	374
2020 Q1	$13.6M	Buy	777,200 +55,463	+8%	+$1.16M	0.03%	430
2019 Q4	$12.6M	Sell	721,737 -45,620	-6%	-$759K	0.02%	530
2019 Q3	$11.8M	Buy	767,357 +28,009	+4%	+$535K	0.02%	499
2019 Q2	$15.3M	Buy	+739,348	New	+$16.6M	0.03%	444

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management (UK)'s DNLI Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Denali Therapeutics (DNLI) stake by 0.59% in Q2 2021, buying an estimated $178K and bringing the position to 491,372 shares worth $38.5M. The position accounts for 0.04% of the portfolio, ranked #396.

Pictet Asset Management (UK) first reported a position in DNLI in Q2 2019 and has held it in 9 quarters since. The position peaked at $53.6M in Q4 2020. 210 funds tracked by Wall St. Rank hold DNLI as of Q2 2021.

Pictet Asset Management (UK) held 491,372 shares of Denali Therapeutics worth $38.5M as of Q2 2021.
Pictet Asset Management (UK) bought 2,873 Denali Therapeutics shares in Q2 2021, an estimated $178K.
Denali Therapeutics made up 0.04% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #396 holding.
Pictet Asset Management (UK) first reported a position in Denali Therapeutics in Q2 2019 and has held it in 9 quarters since.
Pictet Asset Management (UK)'s Denali Therapeutics position peaked at $53.6M in Q4 2020.
210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.